We address well-being mainly through our solutions for life innovation and safety. We have deep experience in process control, as well as a record of successful co-innovation with customers doing business in the medical facilities, food, resources, and other fields. We leverage these experiences and expertise solutions ranging from research and development to production and distribution services, facilitating safe and healthy lifestyles for all.
|Related SDGs||Summary of value creation stories||Sustainability KPIs||Targets for FY30|
|Support people’s health and prosperity through provision of life-innovation solutions and assurance of safe and comfortable workplaces||Health and safety value creation||1 trillion yen|
Health and safety value creation; Contribution to customer/social health and safety through the life innovation and safety fields
|Related SDGs||Value creation themes||Sustainability KPIs||Results of FY17||Targets for FY20|
|Improved productivity in manufacturing/processing of pharmaceuticals/foods||Amount of productivity improvement of pharmaceutical and food customers||(Base year)||Doubled|
|Support development of drugs and biopharmaceuticals||Number of provided drug discovery systems||(Base year)||Twenty times|
|Improvement of safety||Number of shipped safety instrumented system controller units||2,300||3,200|
|On-site maintenance solutions||Number of provided on-site maintenance solutions||250||850|
1 Improved productivity in manufacturing/processing of pharmaceuticals/foods
We leverage our technologies in measurement, control, and information, combined with our experience across a range of industries, to introduce leaps forward in production throughout the entire value chain, from basic research to logistics and services.
2 Support development of drugs and biopharmaceuticals
We support efficient development and production of highly safe pharmaceuticals through drug discovery support technologies including confocal microscopes, cell image analysis, and bioreactors.
3 Improvement of safety
We contribute to improved safety at customer plants through integrated process control and safety instrumented systems, operating training simulators, cyber security solutions, and other safety solutions.
4 On-site maintenance solutions
We provide facilities management and consulting that result in low-workload, safe and efficient plant management.
Support bio antibody and other leading-edge drug development and production through solutions and services
Reduce cost of drug discovery significantly and develop highly effective leading-edge pharmaceuticals rapidly
Leading-edge pharmaceuticals and treatments available more quickly to more people
Sustainable Development Goal 3 is to “Ensure healthy lives and promote well-being for all at all ages.” This goal emphasizes the importance of research and development leading to creation of innovative drugs. Yokogawa was one of the first companies to be active in this field. The confocal microscope is one example of our contributions. This equipment has made a major contribution to explain the mechanisms behind the mysteries and illnesses of life that have been veiled for so long in basic medical and biological research and development. Today, our confocal microscopes are being used in prominent research projects in the fields of molecular biology and genetic engineering. These research projects are said to be candidates for future Nobel Prize consideration.
We have created a drug discovery support system based on confocal microscope imaging technology, image processing technology, and AI technology. This system facilitates the rapid screening of the efficacy and toxicity of an enormous number of sample compounds, dramatically reducing the time and cost involved in drug discovery.
Yokogawa is involved in research and development for single-cell solutions in medical treatments. Single-cell solutions are techniques that use confocal imaging to accurate recover and analyze the constituents of a single target cell. This technology is vital for explaining the diversity and interaction mechanisms of individual cells, and is hoped to be used in simple specific diagnosis of cancer and in individual medical treatments using applications of genetic engineering.
We also plan to enter the fields of biopharmaceuticals (medicines produced by cells) and regenerative medicine (using cells) in the future. We believe applications of Yokogawa measurement, control, and information technologies for cell research and development will improve the productivity of innovative biopharmaceuticals. And, by managing information across the entire value chain, we will be able to generate improvements in quality and efficiency. Many regions across the world, particularly in the emerging countries of Asia, are waiting eagerly for advanced drugs and medical treatments. Yokogawa solutions and services will play an important role in providing advanced drug and medical treatments to more people more rapidly.
- Message from Employee -
Single-cell gene analysis is one single-cell solution that makes composite analysis of individual cell morphological information and gene expression possible for the first time. My role is to secure technologies that provide for the stable recovery of genes from extracted cells. I am involved in equipment development and improving sample extraction equipment. At the same time, I conduct experiments in ways to recover trace amounts of genes from a single cell. We believe this technology is effective in uncovering the role of organoids*1 produced in cancer tissue and iPS cells, as well as other individual cells from within heterogeneous*2 aggregations. I hope that Yokogawa systems can be useful in people's lives, contributing to the development of cancer treatment and regenerative medicine.
*1 Organs created in 3D in test tubes, etc.
*2 Mixture of different types of cells
Tomoko Hirai Bio Solution Center R&D, Life Innovation Business Headquarters, Yokogawa Electric Corporation
Yokogawa concluded a distributor agreement with a local company in Saudi Arabia in 1970s to start cultivating the control system market. Having established Yokogawa Saudi Arabia in 2006 and Yokogawa Services Saudi Arabia in 2007, Yokogawa has accumulated a track record in the key oil and gas sector and has expanded business led by local employees. Yokogawa's customers in Saudi Arabia are mainly state-owned enterprises. As well as contributing to Saudi Arabia's industrial development by helping customers resolve their issues, Yokogawa has been addressing the resolution of the nation's social issue since the inception of these companies. In recent years, a high youth unemployment rate in line with the increase of foreign workers has become a pressing issue in Saudi Arabia. The Saudi government is implementing a policy to increase employment opportunities by promoting employment of Saudi nationals (Saudization). While expanding business in Saudi Arabia, Yokogawa is supporting human resources development in the country in cooperation with local universities and other educational institutions and providing employment opportunities.
Based on a memorandum of understanding signed with the King Fahd University of Petroleum and Minerals (KFUPM) and three other universities in Saudi Arabia concerning human resources training programs, Yokogawa provides engineering training and short-term internships for students and new graduates. In the 10 years from 2007, of 275 people who completed the training program, 63 joined the Yokogawa Group.
As of June 2017, Yokogawa's subsidiaries in Saudi Arabia had 300 employees of whom 135 were Saudi nationals (75 men and 60 women), with a Saudization percentage of 45%. According to the criteria for the ratio of Saudi nationals to the workforce of companies specified by the Ministry of Labor of Saudi Arabia, Yokogawa subsidiaries are in the top level in the six-level ranking.
Yokogawa is vigorously supporting advancement of Saudi Arabian women and has hired some 150 local women since 2010. Of the current 60 female employees, 50 are engaged in engineering work. Initiatives to resolve social issues of Saudi Arabia have a great significance in the context of Yokogawa's sustainable development of business in the country. Yokogawa continues to address issues of customers in Saudi Arabia and national issues with devotion in order to contribute to the country's industrial development while enhancing Yokogawa's corporate value.
President Nishijima (left) had an audience with Custodian of the Two Holy Mosques King Salman Bin Abdulaziz Al-Saud, King of the Kingdom of Saudi Arabia, at Saudi-Japan Vision 2030 Business Forum in March 2017 during the King's visit to Japan.
At the Business Forum, Yokogawa concluded a MOU with Saudi Arabian Oil Company (Saudi Aramco) concerning cooperation in R&D and human resources development in the measuring and control fields of the oil, petrochemical, and gas sector.